t(11;14) Multiple Myeloma and Role of Venetoclax 

In this episode, we discuss the biology and management of t(11;14) multiple myeloma and the role of venetoclax with Dr. Rafael Fonseca and Dr. Martin Kaiser.
Here are the shownotes:
1. Excellent tweetorial thread by Dr. Fonseca highlighting some of the historical studies that identified t(11;14) and its prognostic impact in myeloma:
x.com/Rfonsi1/status/12060049...
2. Natural history of t(11;14) myeloma in the era of PIs and IMiDs:
pubmed.ncbi.nlm.nih.gov/28655...
3. BELLINI trial (Ven-Bort-Dex vs Bort-Dex in all-comers):
pubmed.ncbi.nlm.nih.gov/33129...
4. Efficacy of Dara-VCD by cytogenetic subgroups in AL Amyloidosis:
pubmed.ncbi.nlm.nih.gov/36779...
5. CANOVA Trial (Ven-Dex vs Pom-Dex in t[11;14]):
www.clinical-lymphoma-myeloma...
6. Phase 1/2 trial on Daratumumab-Venetoclax-Dex in Relapsed/Refractory Myeloma:
pubmed.ncbi.nlm.nih.gov/34388...
7. Phase 1/2 trial on venetoclax-carfilzomib-dex in relapsed/refractory myeloma:
pubmed.ncbi.nlm.nih.gov/34470...